bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Methods from Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Authors: Gris-Oliver Albert , Palafox Marta , Monserrat Laia , Brasó-Maristany Fara , Òdena Andreu , Sánchez-Guixé Mònica , Ibrahim Yasir H. , Villacampa Guillermo , Grueso Judit , Parés Mireia , Guzmán Marta , Rodríguez Olga , Bruna Alejandra , Hirst Caroline S. , Barnicle Alan , de Bruin Elza C. , Reddy Avinash , Schiavon Gaia , Arribas Joaquín , Mills Gordon B. , Caldas Carlos , Dienstmann Rodrigo , Prat Aleix , Nuciforo Paolo , Razavi Pedram , Scaltriti Maurizio , Turner Nicholas C. , Saura Cristina , Davies Barry R. , Oliveira Mafalda , Serra Violeta
Published: April 2023

Supplementary Methods
Supplementary Data Legends from Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts
Authors: Gris-Oliver Albert , Palafox Marta , Monserrat Laia , Brasó-Maristany Fara , Òdena Andreu , Sánchez-Guixé Mònica , Ibrahim Yasir H. , Villacampa Guillermo , Grueso Judit , Parés Mireia , Guzmán Marta , Rodríguez Olga , Bruna Alejandra , Hirst Caroline S. , Barnicle Alan , de Bruin Elza C. , Reddy Avinash , Schiavon Gaia , Arribas Joaquín , Mills Gordon B. , Caldas Carlos , Dienstmann Rodrigo , Prat Aleix , Nuciforo Paolo , Razavi Pedram , Scaltriti Maurizio , Turner Nicholas C. , Saura Cristina , Davies Barry R. , Oliveira Mafalda , Serra Violeta
Published: April 2023

Supplementary Data Legends
Supplementary Figures from IFNL4-ΔG Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer
Authors: Tang Wei , Wallace Tiffany A. , Yi Ming , Magi-Galluzzi Cristina , Dorsey Tiffany H. , Onabajo Olusegun O. , Obajemu Adeola , Jordan Symone V. , Loffredo Christopher A. , Stephens Robert M. , Silverman Robert H. , Stark George R. , Klein Eric A. , Prokunina-Olsson Ludmila , Ambs Stefan
Published: April 2023

Supplementary Figure 1. Expression of IFNL4 after transfection of human prostate cancer cell lines with the IFNL4-Halo construct; Supplementary Figure 2. Expression of two interferon signatures, IRG and IRDS, in cultured prostate cancer epithelial cells from 14 African-American and 13 European-American men; Supplementary Figure 3. Association of IFNL4 SNP rs12979860-T allele with decreased overall survival among African-American prostate cancer patients in the Cleveland Clinic cohort (n = 197).
Supplementary Data from Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Authors: Spring Laura M. , Fell Geoffrey , Arfe Andrea , Sharma Chandni , Greenup Rachel , Reynolds Kerry L. , Smith Barbara L. , Alexander Brian , Moy Beverly , Isakoff Steven J. , Parmigiani Giovanni , Trippa Lorenzo , Bardia Aditya
Published: April 2023

Online supplement
Supplementary Table 1 from First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors
Authors: McLeod Robert , Kumar Rajiv , Papadatos-Pastos Dionysis , Mateo Joaquin , Brown Jessica S. , Garces Alvaro H. Ingles , Ruddle Ruth , Decordova Shaun , Jueliger Simone , Ferraldeschi Roberta , Maiques Oscar , Sanz-Moreno Victoria , Jones Paul , Traub Stephanie , Halbert Gavin , Mellor Sarah , Swales Karen E. , Raynaud Florence I. , Garrett Michelle D. , Banerji Udai
Published: April 2023

Demographic Profile
Supplementary Data from First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors
Authors: McLeod Robert , Kumar Rajiv , Papadatos-Pastos Dionysis , Mateo Joaquin , Brown Jessica S. , Garces Alvaro H. Ingles , Ruddle Ruth , Decordova Shaun , Jueliger Simone , Ferraldeschi Roberta , Maiques Oscar , Sanz-Moreno Victoria , Jones Paul , Traub Stephanie , Halbert Gavin , Mellor Sarah , Swales Karen E. , Raynaud Florence I. , Garrett Michelle D. , Banerji Udai
Published: April 2023

Inclusion/Exclusion Criteria and Pharmacokinetic Analytical Method
Supplementary Data from Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients
Authors: Osti Daniela , Del Bene Massimiliano , Rappa Germana , Santos Mark , Matafora Vittoria , Richichi Cristina , Faletti Stefania , Beznoussenko Galina V. , Mironov Alexandre , Bachi Angela , Fornasari Lorenzo , Bongetta Daniele , Gaetani Paolo , DiMeco Francesco , Lorico Aurelio , Pelicci Giuliana
Published: April 2023

Figure S3
Supplementary Figure S4 from Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma
Authors: Pareja Fresia , Brown David N. , Lee Ju Youn , Da Cruz Paula Arnaud , Selenica Pier , Bi Rui , Geyer Felipe C. , Gazzo Andrea , da Silva Edaise M. , Vahdatinia Mahsa , Stylianou Anthe A. , Ferrando Lorenzo , Wen Hannah Y. , Hicks James B. , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Figure S4 shows the clonal relatedness, clonal decomposition and phylogenetic analysis of synchronously diagnosed ductal carcinoma in situ and invasive breast cancers.
Supplementary Figure S3 from Whole-Exome Sequencing Analysis of the Progression from Non–Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma
Authors: Pareja Fresia , Brown David N. , Lee Ju Youn , Da Cruz Paula Arnaud , Selenica Pier , Bi Rui , Geyer Felipe C. , Gazzo Andrea , da Silva Edaise M. , Vahdatinia Mahsa , Stylianou Anthe A. , Ferrando Lorenzo , Wen Hannah Y. , Hicks James B. , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

Supplementary Figure S3 shows the copy number profiles of ductal carcinomas in situ (DCIS) and invasive ductal carcinomas of no special type (IDC-NST), and frequency of most commonly mutated genes in DCIS, compared to luminal B IDC-NSTs, and according to ER/HER2 status.
Figure S6. Serum Cytokines (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Authors: Wainberg Zev A. , Hochster Howard S. , Kim Edward J. , George Ben , Kaylan Aparna , Chiorean E. Gabriela , Waterhouse David M. , Guiterrez Martin , Parikh Aparna , Jain Rishi , Carrizosa Daniel Ricardo , Soliman Hatem H. , Lila Thomas , Reiss David J. , Pierce Daniel W. , Bhore Rafia , Banerjee Sibabrata , Lyons Larry , Louis Chrystal U. , Ong Teng Jin , O'Dwyer Peter J.
Published: April 2023

Concentrations of CXCL10 (A) and sIL2Rα (B) at baseline and peak on-treatment values. Investigator-assessed PFS in patients with high or low serum cytokines CXCL10 (C) and sIL2Rα (D). CXCL10, interferon gamma-induced protein 10; mo, months; NE, not estimable; NR, nonresponder; PFS, progression-free survival; R, responder; sIL2Rα, soluble form of interleukin 2 receptor alpha; Tx, treatment.
Figure S1. Study Design from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Authors: Wainberg Zev A. , Hochster Howard S. , Kim Edward J. , George Ben , Kaylan Aparna , Chiorean E. Gabriela , Waterhouse David M. , Guiterrez Martin , Parikh Aparna , Jain Rishi , Carrizosa Daniel Ricardo , Soliman Hatem H. , Lila Thomas , Reiss David J. , Pierce Daniel W. , Bhore Rafia , Banerjee Sibabrata , Lyons Larry , Louis Chrystal U. , Ong Teng Jin , O'Dwyer Peter J.
Published: April 2023

Patients were enrolled in Arm B Part 1 after the safety oversight committee deemed Arm A Part 1 safe. DRC, data review committee; LAPC, locally advanced pancreatic cancer; MPC, metastatic pancreatic cancer; RP2D, recommended Part 2 dose.
Supplementary Table 2 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Authors: Wang Yifan , Park Jin Yong Patrick , Pacis Alain , Denroche Robert E. , Jang Gun Ho , Zhang Amy , Cuggia Adeline , Domecq Celine , Monlong Jean , Raitses-Gurevich Maria , Grant Robert C. , Borgida Ayelet , Holter Spring , Stossel Chani , Bu Simeng , Masoomian Mehdi , Lungu Ilinca M. , Bartlett John M.S. , Wilson Julie M. , Gao Zu-Hua , Riazalhosseini Yasser , Asselah Jamil , Bouganim Nathaniel , Cabrera Tatiana , Boucher Louis-Martin , Valenti David , Biagi James , Greenwood Celia M.T. , Polak Paz , Foulkes William D. , Golan Talia , O'Kane Grainne M. , Fischer Sandra E. , Knox Jennifer J. , Gallinger Steven , Zogopoulos George
Published: April 2023

Supplementary Table 2 shows the clinical characteristics of 21 HRD PDAC patients whose tumours were whole genome and whole transcriptome sequenced
Supplementary Table 1 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Authors: Wang Yifan , Park Jin Yong Patrick , Pacis Alain , Denroche Robert E. , Jang Gun Ho , Zhang Amy , Cuggia Adeline , Domecq Celine , Monlong Jean , Raitses-Gurevich Maria , Grant Robert C. , Borgida Ayelet , Holter Spring , Stossel Chani , Bu Simeng , Masoomian Mehdi , Lungu Ilinca M. , Bartlett John M.S. , Wilson Julie M. , Gao Zu-Hua , Riazalhosseini Yasser , Asselah Jamil , Bouganim Nathaniel , Cabrera Tatiana , Boucher Louis-Martin , Valenti David , Biagi James , Greenwood Celia M.T. , Polak Paz , Foulkes William D. , Golan Talia , O'Kane Grainne M. , Fischer Sandra E. , Knox Jennifer J. , Gallinger Steven , Zogopoulos George
Published: April 2023

Supplementary Table 1 shows the clinical characteristics of the patients from whom patient-derived xenografts were generated and evaluated in the preclinical trial
Supplementary Figure 2 from The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia
Authors: Verbeke Delphine , Demeyer Sofie , Prieto Cristina , de Bock Charles E. , De Bie Jolien , Gielen Olga , Jacobs Kris , Mentens Nicole , Verhoeven Bronte Manouk , Uyttebroeck Anne , Boeckx Nancy , De Keersmaecker Kim , Maertens Johan , Segers Heidi , Cools Jan
Published: April 2023

Suppl. figure 2: PDX samples have different basal NR3C1 expression levels.
Figure S1-S5 and Table S1-S3 from Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Authors: Matos Ignacio , Martin-Liberal Juan , García-Ruiz Alonso , Hierro Cinta , Ochoa de Olza Maria , Viaplana Cristina , Azaro Analia , Vieito Maria , Braña Irene , Mur Gemma , Ros Javier , Mateos Jose , Villacampa Guillermo , Berché Roger , Oliveira Mafalda , Alsina Maria , Elez Elena , Oaknin Ana , Muñoz-Couselo Eva , Carles Joan , Felip Enriqueta , Rodón Jordi , Tabernero Josep , Dienstmann Rodrigo , Perez-Lopez Raquel , Garralda Elena
Published: April 2023

Figure S1. Flowchart of study selection process with ICIs treatment. Figure S2. Flowchart of study selection process with TAs treatment. Figure S3. Overall Survival comparing HPD with non-HPD in patients with progression disease as best response in the ICIs and TAs cohorts ( RECIST 1.1 progression disease Landmark Analysis). Figure S4. Overall Survival in second line (a) and third (b) setting HPD vs non-HPD progressors by RECIST criteria in ICIs cohort. Figure S5. Concordance between RECIST and TGR criteria in ICIs cohort. Table S1. Computed tomography (CT) acquisition protocol parameters. Table S2. Clinical variables in patients treated with TAs. Table S3. Multivariate model in patients with progression disease as best response in ICIs group (using TGR).
Supplementary Data from Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Authors: Kyriakopoulos Christos E. , Eickhoff Jens C. , Ferrari Anna C. , Schweizer Michael T. , Wargowski Ellen , Olson Brian M. , McNeel Douglas G.
Published: April 2023

Supplementary figure legends
Supplementary Figure 2 from A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
Authors: Wang Yifan , Park Jin Yong Patrick , Pacis Alain , Denroche Robert E. , Jang Gun Ho , Zhang Amy , Cuggia Adeline , Domecq Celine , Monlong Jean , Raitses-Gurevich Maria , Grant Robert C. , Borgida Ayelet , Holter Spring , Stossel Chani , Bu Simeng , Masoomian Mehdi , Lungu Ilinca M. , Bartlett John M.S. , Wilson Julie M. , Gao Zu-Hua , Riazalhosseini Yasser , Asselah Jamil , Bouganim Nathaniel , Cabrera Tatiana , Boucher Louis-Martin , Valenti David , Biagi James , Greenwood Celia M.T. , Polak Paz , Foulkes William D. , Golan Talia , O'Kane Grainne M. , Fischer Sandra E. , Knox Jennifer J. , Gallinger Steven , Zogopoulos George
Published: April 2023

Supplementary Figure 2 shows the results of a pilot monotherapy trial to evaluate regimen-related toxicity
Supplementary figure S2 from Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using 111In-Labeled SGM-101
Authors: de Gooyer Jan Marie , Elekonawo Fortuné M.K. , Bos Desirée L. , van der Post Rachel S. , Pèlegrin André , Framery Bérénice , Cailler Françoise , Vahrmeijer Alexander L. , de Wilt Johannes H.W. , Rijpkema Mark
Published: April 2023

Biodistribution in mice with subcutaneous LS174T tumors at 24, 48 and 72 hours after injection of 30 μg of [111In]In-DTPA-SGM-101.
Supplementary figure S1 from Multimodal CEA-Targeted Image-Guided Colorectal Cancer Surgery using 111In-Labeled SGM-101
Authors: de Gooyer Jan Marie , Elekonawo Fortuné M.K. , Bos Desirée L. , van der Post Rachel S. , Pèlegrin André , Framery Bérénice , Cailler Françoise , Vahrmeijer Alexander L. , de Wilt Johannes H.W. , Rijpkema Mark
Published: April 2023

Absorption and emission of SGM-101 and DTPA-SGM-101. Measurements shown from 500 to nanometer, in steps of 5 nanometer.
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Authors: Byrd John C. , Furman Richard R. , Coutre Steven E. , Flinn Ian W. , Burger Jan A. , Blum Kristie , Sharman Jeff P. , Wierda William , Zhao Weiqiang , Heerema Nyla A. , Luan Ying , Liu Emily A. , Dean James P. , O'Brien Susan
Published: April 2023

Supplementary Fig. S1: Progression-free survival in the following subgroups: (A) by number of prior lines of therapy; (B) by complex karyotype with del(17p) and without del(17p) in the relapsed/refractory setting; (C) with and without lymphocytosis at 1 year; (D) with and without lymphocytosis at 2 years; (E) CR/PR or PR-L within the first 364 days on study; (F) by age
Supplementary Data from A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer
Authors: Hipp Susanne , Voynov Vladimir , Drobits-Handl Barbara , Giragossian Craig , Trapani Francesca , Nixon Andrew E. , Scheer Justin M. , Adam Paul J.
Published: April 2023

Supplementary Tables and Figures
Supplementary Movie S2 from TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions
Authors: Cohen Allison S. , Li Jun , Hight Matthew R. , McKinley Eliot , Fu Allie , Payne Adria , Liu Yang , Zhang Dawei , Xie Qing , Bai Mingfeng , Ayers Gregory D. , Tantawy Mohammed Noor , Smith Jarrod A. , Revetta Frank , Washington M. Kay , Shi Chanjuan , Merchant Nipun , Manning H. Charles
Published: April 2023

Real-time image-guided surgery of Ptf1a-Cre;LSL-KrasG12D/+;Smad4fl/fl (KSC) mouse using V-1520
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Authors: Byrd John C. , Furman Richard R. , Coutre Steven E. , Flinn Ian W. , Burger Jan A. , Blum Kristie , Sharman Jeff P. , Wierda William , Zhao Weiqiang , Heerema Nyla A. , Luan Ying , Liu Emily A. , Dean James P. , O'Brien Susan
Published: April 2023

Supplementary Table S2: Grade 3 or higher AEs in patients receiving ibrutinib in the first-line or relapsed/refractory treatment settings
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Authors: Byrd John C. , Furman Richard R. , Coutre Steven E. , Flinn Ian W. , Burger Jan A. , Blum Kristie , Sharman Jeff P. , Wierda William , Zhao Weiqiang , Heerema Nyla A. , Luan Ying , Liu Emily A. , Dean James P. , O'Brien Susan
Published: April 2023

Supplementary Table S3: Grade 3 or higher infections in patients receiving ibrutinib in the first-line or relapsed/refractory treatment settings
Supplementary Data from Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
Authors: Byrd John C. , Furman Richard R. , Coutre Steven E. , Flinn Ian W. , Burger Jan A. , Blum Kristie , Sharman Jeff P. , Wierda William , Zhao Weiqiang , Heerema Nyla A. , Luan Ying , Liu Emily A. , Dean James P. , O'Brien Susan
Published: April 2023

Supplementary Table S4: Malignancies in patients receiving ibrutinib in the first-line or relapsed/refractory treatment settings
Supplementary Figure S6 from TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions
Authors: Cohen Allison S. , Li Jun , Hight Matthew R. , McKinley Eliot , Fu Allie , Payne Adria , Liu Yang , Zhang Dawei , Xie Qing , Bai Mingfeng , Ayers Gregory D. , Tantawy Mohammed Noor , Smith Jarrod A. , Revetta Frank , Washington M. Kay , Shi Chanjuan , Merchant Nipun , Manning H. Charles
Published: April 2023

In vivo optical imaging of pancreatic lesions using V-1520
Supplementary Figure S5 from TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions
Authors: Cohen Allison S. , Li Jun , Hight Matthew R. , McKinley Eliot , Fu Allie , Payne Adria , Liu Yang , Zhang Dawei , Xie Qing , Bai Mingfeng , Ayers Gregory D. , Tantawy Mohammed Noor , Smith Jarrod A. , Revetta Frank , Washington M. Kay , Shi Chanjuan , Merchant Nipun , Manning H. Charles
Published: April 2023

Blocking of V-1520 binding to TSPO
Supplementary Data from Mismatch Repair–Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy
Authors: Cercek Andrea , Dos Santos Fernandes Gustavo , Roxburgh Campbell S. , Ganesh Karuna , Ng Shu , Sanchez-Vega Francisco , Yaeger Rona , Segal Neil H. , Reidy-Lagunes Diane L. , Varghese Anna M. , Markowitz Arnold , Wu Chao , Szeglin Bryan , Sauvé Charles-Etienne Gabriel , Salo-Mullen Erin , Tran Christina , Patel Zalak , Krishnan Asha , Tkachuk Kaitlyn , Nash Garrett M. , Guillem Jose , Paty Philip B. , Shia Jinru , Schultz Nikolaus , Garcia-Aguilar Julio , Diaz Luis A. , Goodman Karyn , Saltz Leonard B. , Weiser Martin R. , Smith J. Joshua , Stadler Zsofia K.
Published: April 2023

Supplementary Methods and Supplementary Table 1
Supplementary Data from TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions
Authors: Cohen Allison S. , Li Jun , Hight Matthew R. , McKinley Eliot , Fu Allie , Payne Adria , Liu Yang , Zhang Dawei , Xie Qing , Bai Mingfeng , Ayers Gregory D. , Tantawy Mohammed Noor , Smith Jarrod A. , Revetta Frank , Washington M. Kay , Shi Chanjuan , Merchant Nipun , Manning H. Charles
Published: April 2023

Supplementary Information including Supplementary Tables S1, S2 and S3 and Legends for Supplementary Movies S1 and S2
Figure S3 from CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma
Authors: Cannon Andrew , Thompson Christopher M. , Maurer H. Carlo , Atri Pranita , Bhatia Rakesh , West Sean , Ghersi Dario , Olive Kenneth P. , Kumar Sushil , Batra Surinder K.
Published: April 2023

CXCR3-ligand expression with high and low cellularity.
Figure S2 from CXCR3 and Cognate Ligands are Associated with Immune Cell Alteration and Aggressiveness of Pancreatic Ductal Adenocarcinoma
Authors: Cannon Andrew , Thompson Christopher M. , Maurer H. Carlo , Atri Pranita , Bhatia Rakesh , West Sean , Ghersi Dario , Olive Kenneth P. , Kumar Sushil , Batra Surinder K.
Published: April 2023

CD25 expression with T-cell activation.
Supplementary Data from Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Authors: Bruun Jarle , Kryeziu Kushtrim , Eide Peter W. , Moosavi Seyed H. , Eilertsen Ina A. , Langerud Jonas , Røsok Bård , Totland Max Z. , Brunsell Tuva H. , Pellinen Teijo , Saarela Jani , Bergsland Christian H. , Palmer Hector G. , Brudvik Kristoffer W. , Guren Tormod , Dienstmann Rodrigo , Guren Marianne G. , Nesbakken Arild , Bjørnbeth Bjørn Atle , Sveen Anita , Lothe Ragnhild A.
Published: April 2023

Supplementary tables
Supplementary Methods from Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer
Authors: Perkons Nicholas R. , Johnson Omar , Pilla Gabrielle , Profka Enri , Mercadante Michael , Ackerman Daniel , Gade Terence P.F.
Published: April 2023

Supplementary Methods
Figure S1 from Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma
Authors: Casey Dana L. , Wexler Leonard H. , Pitter Kenneth L. , Samstein Robert M. , Slotkin Emily K. , Wolden Suzanne L.
Published: April 2023

Tumor mutational age (TMB) by age (p=0.58 for fusion-negative patients, Pearson coefficient = -0.07, R2 = 0.005; and p=0.04 for fusion-positive patients, Pearson coefficient = 0.44, R2 = 0.20)
Supplementary Figure S8 from Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells
Authors: Ichikawa Junya , Yoshida Tatsuya , Isser Ariel , Laino Andressa S. , Vassallo Melinda , Woods David , Kim Sojung , Oelke Mathias , Jones Kristi , Schneck Jonathan P. , Weber Jeffrey S.
Published: April 2023

TCR repertoire analysis of MART-1 Tet+ CD8+ T-cells.
Supplementary Figure S3 from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Authors: Song Yuqin , Zhou Keshu , Zou Dehui , Zhou Jianfeng , Hu Jianda , Yang Haiyan , Zhang Huilai , Ji Jie , Xu Wei , Jin Jie , Lv Fangfang , Feng Ru , Gao Sujun , Guo Haiyi , Zhou Lei , Elstrom Rebecca , Huang Jane , Novotny William , Wei Rachel , Zhu Jun
Published: April 2023

Kaplan-Meier Plots Comparing Duration of Response (A) and Progression-Free Survival (B) Among Patients With and Without TP53-Mutated Tumors
Supplementary Figure S6 from Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells
Authors: Ichikawa Junya , Yoshida Tatsuya , Isser Ariel , Laino Andressa S. , Vassallo Melinda , Woods David , Kim Sojung , Oelke Mathias , Jones Kristi , Schneck Jonathan P. , Weber Jeffrey S.
Published: April 2023

Nano-aAPC expanded MART-1 Tet+ cells from patients pre- and post-PD-1 treatment.
Supplementary Figure S2 from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Authors: Song Yuqin , Zhou Keshu , Zou Dehui , Zhou Jianfeng , Hu Jianda , Yang Haiyan , Zhang Huilai , Ji Jie , Xu Wei , Jin Jie , Lv Fangfang , Feng Ru , Gao Sujun , Guo Haiyi , Zhou Lei , Elstrom Rebecca , Huang Jane , Novotny William , Wei Rachel , Zhu Jun
Published: April 2023

Changes from Baseline in the SPD for Target Lesions vs Best Overall Response as Assessed by IRC
Supplementary Figure S2 from Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells
Authors: Ichikawa Junya , Yoshida Tatsuya , Isser Ariel , Laino Andressa S. , Vassallo Melinda , Woods David , Kim Sojung , Oelke Mathias , Jones Kristi , Schneck Jonathan P. , Weber Jeffrey S.
Published: April 2023

Cytokine analysis of MART-1 Tet+ CD8+ T-cells.
Supplementary Figure S1 from Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells
Authors: Ichikawa Junya , Yoshida Tatsuya , Isser Ariel , Laino Andressa S. , Vassallo Melinda , Woods David , Kim Sojung , Oelke Mathias , Jones Kristi , Schneck Jonathan P. , Weber Jeffrey S.
Published: April 2023

Analysis of phenotype, activation, maturation and checkpoint markers on E + E MART-1 Tet+ CD8+ T-cells.
Supplemental Figure 6 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Authors: Quayle Steven N. , Girgis Natasha , Thapa Dharma R. , Merazga Zohra , Kemp Melissa M. , Histed Alex , Zhao Fan , Moreta Miguel , Ruthardt Paige , Hulot Sandrine , Nelson Alyssa , Kraemer Lauren D. , Beal Dominic R. , Witt Luke , Ryabin Jessica , Soriano Jonathan , Haydock Mark , Spaulding Emily , Ross John F. , Kiener Peter A. , Almo Steven , Chaparro Rodolfo , Seidel Ronald , Suri Anish , Cemerski Saso , Pienta Kenneth J. , Simcox Mary Ellen
Published: April 2023

Supplementary Figure 6. Characterization of E7-specific CD8+ T cells in mice bearing TC-1 tumors.
Supplementary Figures from The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures
Authors: Chen Lingling , Oke Teniola , Siegel Nicholas , Cojocaru Gady , Tam Ada J. , Blosser Richard L. , Swailes Jessica , Ligon John A. , Lebid Andriana , Morris Carol , Levin Adam , Rhee Daniel S. , Johnston Fabian M. , Greer Jonathan B. , Meyer Christian F. , Ladle Brian H. , Thompson Elizabeth D. , Montgomery Elizabeth A. , Choi Woonyoung , McConkey David J. , Anders Robert A. , Pardoll Drew M. , Llosa Nicolas J.
Published: April 2023

Supplementary figures. Figures S1-S5
Supplemental Figure 4 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Authors: Quayle Steven N. , Girgis Natasha , Thapa Dharma R. , Merazga Zohra , Kemp Melissa M. , Histed Alex , Zhao Fan , Moreta Miguel , Ruthardt Paige , Hulot Sandrine , Nelson Alyssa , Kraemer Lauren D. , Beal Dominic R. , Witt Luke , Ryabin Jessica , Soriano Jonathan , Haydock Mark , Spaulding Emily , Ross John F. , Kiener Peter A. , Almo Steven , Chaparro Rodolfo , Seidel Ronald , Suri Anish , Cemerski Saso , Pienta Kenneth J. , Simcox Mary Ellen
Published: April 2023

Supplementary Figure 4. Antitumor activity of mCUE-101 in established TC-1 tumors.
Supplementary Data from The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures
Authors: Chen Lingling , Oke Teniola , Siegel Nicholas , Cojocaru Gady , Tam Ada J. , Blosser Richard L. , Swailes Jessica , Ligon John A. , Lebid Andriana , Morris Carol , Levin Adam , Rhee Daniel S. , Johnston Fabian M. , Greer Jonathan B. , Meyer Christian F. , Ladle Brian H. , Thompson Elizabeth D. , Montgomery Elizabeth A. , Choi Woonyoung , McConkey David J. , Anders Robert A. , Pardoll Drew M. , Llosa Nicolas J.
Published: April 2023

Table components of supplementary figures
Supplemental Figure 3 from CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies
Authors: Quayle Steven N. , Girgis Natasha , Thapa Dharma R. , Merazga Zohra , Kemp Melissa M. , Histed Alex , Zhao Fan , Moreta Miguel , Ruthardt Paige , Hulot Sandrine , Nelson Alyssa , Kraemer Lauren D. , Beal Dominic R. , Witt Luke , Ryabin Jessica , Soriano Jonathan , Haydock Mark , Spaulding Emily , Ross John F. , Kiener Peter A. , Almo Steven , Chaparro Rodolfo , Seidel Ronald , Suri Anish , Cemerski Saso , Pienta Kenneth J. , Simcox Mary Ellen
Published: April 2023

Supplementary Figure 3. Representative gating strategy for the analysis of blood and spleen samples from HLA-A2 transgenic mice.
Supplementary Table III from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts
Authors: Mehta Ranjit K. , Pal Sanjima , Kondapi Koushik , Sitto Merna , Dewar Cuyler , Devasia Theresa , Schipper Matthew J. , Thomas Dafydd G. , Basrur Venkatesha , Pai Manjunath P. , Morishima Yoshihiro , Osawa Yoichi , Pratt William B. , Lawrence Theodore S. , Nyati Mukesh K.
Published: April 2023

Supplementary Table III: Pharmacokinetics Data of AT13387
Supplementary Materials from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Detailed description of the Image Processing Methodology and metric definitions
Supplementary Figure SF12 from Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial
Authors: Rodriguez Gutierrez Daniel , Jones Chris , Varlet Pascale , Mackay Alan , Warren Daniel , Warmuth-Metz Monika , Aliaga Esther Sánchez , Calmon Raphael , Hargrave Darren R. , Cañete Adela , Massimino Maura , Azizi Amedeo A. , Le Deley Marie-Cécile , Saran Frank , Rousseau Raphael F. , Zahlmann Gudrun , Garcia Josep , Vassal Gilles , Grill Jacques , Morgan Paul S. , Jaspan Tim
Published: April 2023

Survival curves of Event Free Survival (EFS) and Overall Survival (OS) of patients with and without leptomeningeal metastatic (LMM) dissemination
Supplementary Figures S1-S5 from 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis
Authors: Jin Sha , Cojocari Dan , Purkal Julie J. , Popovic Relja , Talaty Nari N. , Xiao Yu , Solomon Larry R. , Boghaert Erwin R. , Leverson Joel D. , Phillips Darren C.
Published: April 2023

Supplementary Figures
Figure S7 from Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma
Authors: Mendez Flor , Kadiyala Padma , Nunez Felipe J. , Carney Stephen , Nunez Fernando M. , Gauss Jessica C. , Ravindran Ramya , Pawar Sheeba , Edwards Marta , Garcia-Fabiani Maria Belen , Haase Santiago , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

Neuropathology Toxicicty Assessment
Supplementary Table 6 from Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
Authors: Laurent Anouchka P. , Siret Aurélie , Ignacimouttou Cathy , Panchal Kunjal , Diop M'Boyba , Jenni Silvia , Tsai Yi-Chien , Roos-Weil Damien , Aid Zakia , Prade Nais , Lagarde Stephanie , Plassard Damien , Pierron Gaelle , Daudigeos Estelle , Lecluse Yann , Droin Nathalie , Bornhauser Beat C. , Cheung Laurence C. , Crispino John D. , Gaudry Muriel , Bernard Olivier A. , Macintyre Elizabeth , Barin Bonnigal Carole , Kotecha Rishi S. , Geoerger Birgit , Ballerini Paola , Bourquin Jean-Pierre , Delabesse Eric , Mercher Thomas , Malinge Sebastien
Published: April 2023

List of datasets enriched in murine B cell precursors (GSEA analyses)
Figure S2 from Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma
Authors: Mendez Flor , Kadiyala Padma , Nunez Felipe J. , Carney Stephen , Nunez Fernando M. , Gauss Jessica C. , Ravindran Ramya , Pawar Sheeba , Edwards Marta , Garcia-Fabiani Maria Belen , Haase Santiago , Lowenstein Pedro R. , Castro Maria G.
Published: April 2023

IHC of pERK on SB tumor sections and ICC of pERK1/2, pMEK1/2, and ID1 on DIPG cells
Supplementary Data from Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
Authors: Laurent Anouchka P. , Siret Aurélie , Ignacimouttou Cathy , Panchal Kunjal , Diop M'Boyba , Jenni Silvia , Tsai Yi-Chien , Roos-Weil Damien , Aid Zakia , Prade Nais , Lagarde Stephanie , Plassard Damien , Pierron Gaelle , Daudigeos Estelle , Lecluse Yann , Droin Nathalie , Bornhauser Beat C. , Cheung Laurence C. , Crispino John D. , Gaudry Muriel , Bernard Olivier A. , Macintyre Elizabeth , Barin Bonnigal Carole , Kotecha Rishi S. , Geoerger Birgit , Ballerini Paola , Bourquin Jean-Pierre , Delabesse Eric , Mercher Thomas , Malinge Sebastien
Published: April 2023

Material and Methods, Figure legends
Figure S6 from Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
Authors: Laurent Anouchka P. , Siret Aurélie , Ignacimouttou Cathy , Panchal Kunjal , Diop M'Boyba , Jenni Silvia , Tsai Yi-Chien , Roos-Weil Damien , Aid Zakia , Prade Nais , Lagarde Stephanie , Plassard Damien , Pierron Gaelle , Daudigeos Estelle , Lecluse Yann , Droin Nathalie , Bornhauser Beat C. , Cheung Laurence C. , Crispino John D. , Gaudry Muriel , Bernard Olivier A. , Macintyre Elizabeth , Barin Bonnigal Carole , Kotecha Rishi S. , Geoerger Birgit , Ballerini Paola , Bourquin Jean-Pierre , Delabesse Eric , Mercher Thomas , Malinge Sebastien
Published: April 2023

Effect of MEK inhibition in vitro
Figure S5 from Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
Authors: Laurent Anouchka P. , Siret Aurélie , Ignacimouttou Cathy , Panchal Kunjal , Diop M'Boyba , Jenni Silvia , Tsai Yi-Chien , Roos-Weil Damien , Aid Zakia , Prade Nais , Lagarde Stephanie , Plassard Damien , Pierron Gaelle , Daudigeos Estelle , Lecluse Yann , Droin Nathalie , Bornhauser Beat C. , Cheung Laurence C. , Crispino John D. , Gaudry Muriel , Bernard Olivier A. , Macintyre Elizabeth , Barin Bonnigal Carole , Kotecha Rishi S. , Geoerger Birgit , Ballerini Paola , Bourquin Jean-Pierre , Delabesse Eric , Mercher Thomas , Malinge Sebastien
Published: April 2023

Phenotypic, transcriptomic and genetic validation of PDX models
Supplementary Data from Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years
Authors: Bazarbachi Ali , Schmid Christoph , Labopin Myriam , Beelen Dietrich , Wolfgang Blau Igor , Potter Victoria , Niittyvuopio Riitta , Socié Gerard , Blaise Didier , Sanz Jaime , Ciceri Fabio , Abou Dalle Iman , Spyridonidis Alexandros , Bug Gesine , Esteve Jordi , Savani Bipin N. , Nagler Arnon , Mohty Mohamad
Published: April 2023

Supplementary tables
Figure S1 from Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-cell Leukemia
Authors: Laurent Anouchka P. , Siret Aurélie , Ignacimouttou Cathy , Panchal Kunjal , Diop M'Boyba , Jenni Silvia , Tsai Yi-Chien , Roos-Weil Damien , Aid Zakia , Prade Nais , Lagarde Stephanie , Plassard Damien , Pierron Gaelle , Daudigeos Estelle , Lecluse Yann , Droin Nathalie , Bornhauser Beat C. , Cheung Laurence C. , Crispino John D. , Gaudry Muriel , Bernard Olivier A. , Macintyre Elizabeth , Barin Bonnigal Carole , Kotecha Rishi S. , Geoerger Birgit , Ballerini Paola , Bourquin Jean-Pierre , Delabesse Eric , Mercher Thomas , Malinge Sebastien
Published: April 2023

Incidence of RAS/MAPK activation in pediatric B-ALL+21 and novel transcript fusions found in our pediatric B-ALL cohort.
Supplementary Statistical Section from Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I–Related Plexiform Neurofibromas
Authors: Boal Lauren H. , Glod John , Spencer Melissa , Kasai Miki , Derdak Joanne , Dombi Eva , Ahlman Mark , Beury Daniel W. , Merchant Melinda S. , Persenaire Christianne , Liewehr David J. , Steinberg Seth M. , Widemann Brigitte C. , Kaplan Rosandra N.
Published: April 2023

Supplemental Statistical Section for Pharmacokinetic and Pharmacodynamic studies
Supplementary Data 3 from A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial
Authors: Kloor Matthias , Reuschenbach Miriam , Pauligk Claudia , Karbach Julia , Rafiyan Mohammad-Reza , Al-Batran Salah-Eddin , Tariverdian Mirjam , Jäger Elke , von Knebel Doeberitz Magnus
Published: April 2023

ELISpot Counts
Supplementary Data 2 from A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial
Authors: Kloor Matthias , Reuschenbach Miriam , Pauligk Claudia , Karbach Julia , Rafiyan Mohammad-Reza , Al-Batran Salah-Eddin , Tariverdian Mirjam , Jäger Elke , von Knebel Doeberitz Magnus
Published: April 2023

Systemic Treatment prior to Study Inclusion
Supplementary Figure 2 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Authors: Krop Ian , Abramson Vandana , Colleoni Marco , Traina Tiffany , Holmes Frankie , Garcia-Estevez Laura , Hart Lowell , Awada Ahmad , Zamagni Claudio , Morris Patrick G. , Schwartzberg Lee , Chan Stephen , Gucalp Ayca , Biganzoli Laura , Steinberg Joyce , Sica Lorenzo , Trudeau Maureen , Markova Denka , Tarazi Jamal , Zhu Zhou , O'Brien Thomas , Kelly Catherine M. , Winer Eric , Yardley Denise A.
Published: April 2023

mRNA expression of (A) AR and (B) ESR1 and correlations between AR and ESR1 in (C) cohort 1 (no prior advanced ET) and (D) cohort 2 (1 prior advanced ET) *R calculated using a Pearson correlation. Abbreviation: ET, endocrine therapy
Supplementary Figure 1B from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Authors: Krop Ian , Abramson Vandana , Colleoni Marco , Traina Tiffany , Holmes Frankie , Garcia-Estevez Laura , Hart Lowell , Awada Ahmad , Zamagni Claudio , Morris Patrick G. , Schwartzberg Lee , Chan Stephen , Gucalp Ayca , Biganzoli Laura , Steinberg Joyce , Sica Lorenzo , Trudeau Maureen , Markova Denka , Tarazi Jamal , Zhu Zhou , O'Brien Thomas , Kelly Catherine M. , Winer Eric , Yardley Denise A.
Published: April 2023

Progression-free survival by subgroup in (A) cohort 1 and (B) cohort 2 HR based on unstratified Cox regression model with <1 favoring enzalutamide arm. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio.
eTable 1 from Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Authors: Stahler Arndt , Stintzing Sebastian , Modest Dominik P. , Ricard Ingrid , Giessen-Jung Clemens , Kapaun Christine , Ivanova Boryana , Kaiser Florian , Fischer von Weikersthal Ludwig , Moosmann Nicolas , Schalhorn Andreas , Stauch Martina , Kiani Alexander , Held Swantje , Decker Thomas , Moehler Markus , Neumann Jens , Kirchner Thomas , Jung Andreas , Heinemann Volker
Published: April 2023

Normalized AREG expression according to baseline characteristics.
Supplementary Figure 1A from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Authors: Krop Ian , Abramson Vandana , Colleoni Marco , Traina Tiffany , Holmes Frankie , Garcia-Estevez Laura , Hart Lowell , Awada Ahmad , Zamagni Claudio , Morris Patrick G. , Schwartzberg Lee , Chan Stephen , Gucalp Ayca , Biganzoli Laura , Steinberg Joyce , Sica Lorenzo , Trudeau Maureen , Markova Denka , Tarazi Jamal , Zhu Zhou , O'Brien Thomas , Kelly Catherine M. , Winer Eric , Yardley Denise A.
Published: April 2023

Progression-free survival by subgroup in (A) cohort 1 and (B) cohort 2 HR based on unstratified Cox regression model with <1 favoring enzalutamide arm. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio.
Supplementary Figure 5 from ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials
Authors: Turner Nicholas C. , Swift Claire , Kilburn Lucy , Fribbens Charlotte , Beaney Matthew , Garcia-Murillas Isaac , Budzar Aman U. , Robertson John F.R. , Gradishar William , Piccart Martine , Schiavon Gaia , Bliss Judith M. , Dowsett Mitch , Johnston Stephen R.D. , Chia Stephen K.
Published: April 2023

Supplementary Figure 5. Progression free survival by ESR1 mutation detected in ctDNA
Supplementary Data from First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Authors: Papadopoulos Kyriakos P. , Johnson Melissa L. , Lockhart Albert C. , Moore Kathleen , Falchook Gerald S. , Formenti Silvia C. , Naing Aung , Carvajal Richard D. , Rosen Lee S. , Weiss Glen J. , Leidner Rom S. , Li Jingjin , Paccaly Anne , Feng Minjie , Stankevich Elizabeth , Lowy Israel , Fury Matthew G. , Crittenden Marka R.
Published: April 2023

Combination of all supplementary materials
Supplementary Figure S9 from Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
Authors: Zugazagoitia Jon , Gupta Swati , Liu Yuting , Fuhrman Kit , Gettinger Scott , Herbst Roy S. , Schalper Kurt A. , Rimm David L.
Published: April 2023

Histograms showing normalized ARG1 counts (A) and signal to background ratios (B) in the CD45 compartment
Supplementary Figure S3 from Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non–Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling
Authors: Zugazagoitia Jon , Gupta Swati , Liu Yuting , Fuhrman Kit , Gettinger Scott , Herbst Roy S. , Schalper Kurt A. , Rimm David L.
Published: April 2023

Representative histograms showing normalized PD-1 counts (A) and signal to background ratios (B) in the CD45 compartment, and normalized LAG3 counts (C) and signal to background ratios (D) in the CD45 compartment, as representative markers with low signal relative to non-specific counts
Supplementary Figure 3-7 from STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Authors: Proia Theresa A. , Singh Maneesh , Woessner Richard , Carnevalli Larissa , Bommakanti Gayathri , Magiera Lukasz , Srinivasan Srimathi , Grosskurth Shaun , Collins Mike , Womack Chris , Griffin Matthew , Ye Minwei , Cantin Susan , Russell Deanna , Xie Mingchao , Hughes Adina , Deng Nanhua , Mele Deanna A. , Fawell Stephen , Barry Simon , Reimer Corinne , Barrett J. Carl , McCoon Patricia
Published: April 2023

Syngeneic mouse tumor efficacy, STAT3, and gene expression changes
Supplementary Figures S1 and S2 from X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis
Authors: Tricarico Rossella , Nicolas Emmanuelle , Hall Michael J. , Golemis Erica A.
Published: April 2023

Location of Mutations in KDM6A and KDM5C
Figure S9. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

HRs for overall survival duration of patients in the discovery cohort for different values for each cytokine evaluated: eotaxin (A), GM-CSF (B), Gro-alpha (C), IL-12p70 (D), IL-13 (E), IL-18 (F), IL-1 beta (G), IL-2 (H), IL-4 (I), IL-5 (J), IL-6 (K), IFN gamma (L), IP-10 (M), MCP-1 (N), MIP-1alpha (O), MIP-1 beta(P), RANTES (Q), SDF-1alpha (R) and TNF-alpha (S).
Table S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Authors: Carrato Cristina , Alameda Francesc , Esteve-Codina Anna , Pineda Estela , Arpí Oriol , Martinez-García Maria , Mallo Mar , Gut Marta , Lopez-Martos Raquel , Barco Sonia Del , Ribalta Teresa , Capellades Jaume , Puig Josep , Gallego Oscar , Mesia Carlos , Muñoz-Marmol Ana M , Archilla Ivan , Arumí Montserrat , Blanc Julie Marie , Bellosillo Beatriz , Menendez Silvia , Esteve Anna , Bagué Silvia , Hernandez Ainhoa , Craven-Bartle Jordi , Fuentes Rafael , Vidal Noemí , Aldecoa Iban , Iglesia Nuria de la , Balana Carmen
Published: April 2023

Key resource identifiers (RRIDs), antibodies, methods, and scoring systems used for immunohistochemistry analyses
Supplementary Table S1 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Authors: Carrato Cristina , Alameda Francesc , Esteve-Codina Anna , Pineda Estela , Arpí Oriol , Martinez-García Maria , Mallo Mar , Gut Marta , Lopez-Martos Raquel , Barco Sonia Del , Ribalta Teresa , Capellades Jaume , Puig Josep , Gallego Oscar , Mesia Carlos , Muñoz-Marmol Ana M , Archilla Ivan , Arumí Montserrat , Blanc Julie Marie , Bellosillo Beatriz , Menendez Silvia , Esteve Anna , Bagué Silvia , Hernandez Ainhoa , Craven-Bartle Jordi , Fuentes Rafael , Vidal Noemí , Aldecoa Iban , Iglesia Nuria de la , Balana Carmen
Published: April 2023

Statistically significant adjusted P-values for differential expression of genes in the pairwise comparison of molecular subtypes. Two of these genes were selected for immunohistochemical analysis for the identification of the mesenchymal subtype.
Supplementary Fig. S2 from Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy
Authors: Carrato Cristina , Alameda Francesc , Esteve-Codina Anna , Pineda Estela , Arpí Oriol , Martinez-García Maria , Mallo Mar , Gut Marta , Lopez-Martos Raquel , Barco Sonia Del , Ribalta Teresa , Capellades Jaume , Puig Josep , Gallego Oscar , Mesia Carlos , Muñoz-Marmol Ana M , Archilla Ivan , Arumí Montserrat , Blanc Julie Marie , Bellosillo Beatriz , Menendez Silvia , Esteve Anna , Bagué Silvia , Hernandez Ainhoa , Craven-Bartle Jordi , Fuentes Rafael , Vidal Noemí , Aldecoa Iban , Iglesia Nuria de la , Balana Carmen
Published: April 2023

Spearman correlation between gene and protein expression for the four antibodies selected according to RNA-Seq differential expression.
Figure S2. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

Kaplan-Meier curves of progression-free survival (A) and overall survival (B) in the discovery cohort population.
Figure S12. from Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer
Authors: Merz Valeria , Zecchetto Camilla , Santoro Raffaela , Simionato Francesca , Sabbadini Fabio , Mangiameli Domenico , Piro Geny , Cavaliere Alessandro , Deiana Michela , Valenti Maria Teresa , Bazan Diana , Fedele Vita , Lonardi Sara , Melisi Davide
Published: April 2023

Kaplan-Meier curves of survival outcomes. Progression-free survival (A) and overall survival (B) in the validation cohort population.